SIR 2024
Interventional Oncology
Takaaki Hasegawa, MD,PhD (he/him/his)
Medical director
Aichi Cancer Center Hospital, Japan
Financial relationships: Full list of relationships is listed on the CME information page.
Yozo Sato, MD
Medical staff
Aichi cancer Center Hospital, Japan
Disclosure information not submitted.
Hidekazu Yamaura, MD
Medical staff
Aichi Cancer Center Hospital, Japan
Disclosure information not submitted.
Shinichi Murata, MD
Medical staff
Aichi Cancer Center Hospital, Japan
Disclosure information not submitted.
Yoshitaka Inaba, n/a
Professor
Aichi Cancer Center Hospital, Japan
Disclosure information not submitted.
: To investigate changes in respiratory function after radiofrequency ablation (RFA) for lung tumors.
Materials and
Methods: Among the patients who underwent RFA for lung tumors from April 2009 to November 2022, those who underwent pulmonary function tests before, early after (within 2 months), and late after treatment (within 2 years after 3 months) were retrospectively evaluated. A total of 21 patients (15 males and 6 females; median age, 63.5 years; range, 40 - 76) were included in this study. The target lesions were 10 primary lung cancers and 11 metastatic lung tumors, with a median tumor size of 12 mm (range, 4 - 21 mm). Seventeen patients had a history of smoking, and the median Brinkman Index (BI) was 500 (range, 0 – 1200). The Vital Capacity (VC) and Forced Expiratory Volume in 1 second (FEV 1.0) of early and late postoperative periods were compared towards preoperative data using the Mann–Whitney U test. The rate of change in VC and FEV1.0 towards preoperative data were also calculated and the risk factors for declining the respiratory function were also evaluated using Mann–Whitney U test with factors of tumor size, tumor origin, tumor location, ablation needle tip, presence of emphysema, surgical history, and BI.
Results: The median preoperative pulmonary function test results were VC: 3.11 L (range, 1.79 – 4.01) and FEV1.0: 1.99 L (range, 0.83 – 2.80). The median postoperative results were VC: 3.04 L (range, 1.74 – 3.90; p = 0.95), FEV1.0: 1.88 L (range, 0.80 – 2.79; p = 0.27) and VC: 3.08L (range, 1.83 – 4.02; p = 0.59) and FEV 1.0: 2.02L (range, 0.81 – 2.83; p = 0.78) for early and late after treatment, respectively. The median rates of change in VC and FEV1.0 were 98.0 % and 96.8 % in the early period and 100.2 % and 98.1 % in the late period. There was significant decline in FEV1.0 in the early postoperative period for patients with BI > 500 (98.9% for BI ≦ 500 and 91.2% for BI > 500, p=0.002).
Conclusion:
RFA for lung tumors is a less invasive treatment with minimal impact on respiratory function. On the other hand, when treating patients with a history of smoking cases with BI > 500, attention should be paid as FEV1.0 tends to decline in the early period after RFA.